Literature DB >> 8930993

Treatment with genetically engineered fibroblasts producing NGF or BDNF can accelerate recovery from traumatic spinal cord injury in the adult rat.

D H Kim1, P H Gutin, L J Noble, D Nathan, J S Yu, R P Nockels.   

Abstract

We tested the hypothesis that NGF or BDNF can protect damaged neural structures following spinal cord injury. Spinal contusions were produced in adult rats by a weight drop method. Thereafter, unmodified Rat 1 fibroblasts or fibroblasts engineered to secrete NGF or BDNF were injected into the injury site. Weekly assessments of recovery were made for 6 weeks using a locomotor rating scale. All rats were immediately paraplegic, then began to recover. At 1 week after injury, the ratings of locomotor performance in rats implanted with NGF- or BDNF-secreting fibroblasts were significantly increased over those of rats implanted with unmodified fibroblasts. This trend toward enhanced recovery persisted during the duration of the experiment, although the difference became smaller. Histological examination after 6 weeks showed a larger cross-sectional area of spinal cord at the maximal injury site in the animals treated with NGF or BDNF. These results demonstrate a significant biological effect of treatment with neurotrophins in traumatic spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930993     DOI: 10.1097/00001756-199609020-00033

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  17 in total

Review 1.  Peripheral nerve regeneration and neurotrophic factors.

Authors:  G Terenghi
Journal:  J Anat       Date:  1999-01       Impact factor: 2.610

2.  Mechanism of GABA receptors involved in spasticity inhibition induced by transcranial magnetic stimulation following spinal cord injury.

Authors:  Wei Gao; Li-Guo Yu; Ya-Li Liu; Yi-Zhao Wang; Xiao-Lin Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

3.  BDNF protects neurons following injury by modulation of caspase activity.

Authors:  Dong H Kim; Xiurong Zhao
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Neural stem cells transplantation alleviate the hyperalgesia of spinal cord injured (SCI) associated with down-regulation of BDNF.

Authors:  Zhi-Gang Yao; Xiao-Li Sun; Peng Li; Hong-Lei Liu; Hai-Long Wu; Zhi-Qiang Xi; Zhong-Hui Zheng
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Grafts of brain-derived neurotrophic factor and neurotrophin 3-transduced primate Schwann cells lead to functional recovery of the demyelinated mouse spinal cord.

Authors:  Christelle Girard; Alexis-Pierre Bemelmans; Noëlle Dufour; Jacques Mallet; Corinne Bachelin; Brahim Nait-Oumesmar; Anne Baron-Van Evercooren; François Lachapelle
Journal:  J Neurosci       Date:  2005-08-31       Impact factor: 6.167

6.  Brain-derived neurotrophic factor concentrations in tetraplegic athletes.

Authors:  S Zeller; T Abel; S Rojas-Vega; T Foitschik; H K Strueder
Journal:  Spinal Cord       Date:  2015-06-16       Impact factor: 2.772

7.  Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury.

Authors:  Antonio Chiaretti; Marco Piastra; Giancarlo Polidori; Concezio Di Rocco; Elena Caresta; Alessia Antonelli; Tiziana Amendola; Luigi Aloe
Journal:  Intensive Care Med       Date:  2003-07-05       Impact factor: 17.440

Review 8.  Cytokine transport across the injured blood-spinal cord barrier.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Preparation of brain-derived neurotrophic factor- and neurotrophin-3-secreting Schwann cells by infection with a retroviral vector.

Authors:  S T Sayers; N Khan; Y Ahmed; R Shahid; T Khan
Journal:  J Mol Neurosci       Date:  1998-04       Impact factor: 3.444

10.  Bone Marrow Stromal Cell Intraspinal Transplants Fail to Improve Motor Outcomes in a Severe Model of Spinal Cord Injury.

Authors:  John H Brock; Lori Graham; Eileen Staufenberg; Eileen Collyer; Jacob Koffler; Mark H Tuszynski
Journal:  J Neurotrauma       Date:  2015-11-13       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.